A Phase I Study of PLX8394 Plus Ritonavir in Children with Recurrent or Progressive BRAF Activated Gliomas
Principal Institutions: Children’s Hospital of Los Angeles in...
A Phase I Study of PLX8394 Plus Ritonavir in Children with Recurrent or Progressive BRAF Activated Gliomas
Principal Institutions: Children’s Hospital of Los Angeles in...
https://www.cancertalkfoundation.org/post/living-through-covid-19-as-a-cancer-patient-or-survivor submitted by /u/CancerTalkFoundation
Continue Reading to the Source
Save the date: Coalition Connection: COVID-19 on 4 February
06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET
On 4th February 2021, the Global Cancer Coalitions Network...
First Coalition Connection event sees publication of report showing devastating impact of COVID-19 on cancer organisations
On 4th February 2021, the Global Cancer Coalitions Network...
Save the date: Coalition Connection: COVID-19 on 4 February
06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET
On 4th February 2021, the Global Cancer Coalition Network...
Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...
A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...
Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...
Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...
Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...
The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...
Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...
The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...
Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...
A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...
Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...
